A number of other analysts have also issued reports on OMER. Maxim Group set a $24.00 price target on shares of Omeros and gave the stock a buy rating in a research note on Thursday, February 15th. ValuEngine lowered shares of Omeros from a hold rating to a sell rating in a research note on Wednesday, February 14th. Zacks Investment Research lowered shares of Omeros from a buy rating to a hold rating in a research note on Wednesday, October 25th. Bank of America upped their target price on shares of Omeros from $2.44 to $4.00 in a research note on Wednesday, February 14th. Finally, Wedbush restated an outperform rating and set a $47.00 target price on shares of Omeros in a research note on Tuesday, November 28th. One analyst has rated the stock with a sell rating, four have issued a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of Buy and an average target price of $30.38.
Shares of Omeros (NASDAQ OMER) opened at $9.00 on Monday. The company has a debt-to-equity ratio of 8.99, a quick ratio of 4.74 and a current ratio of 4.77. The stock has a market cap of $432.03, a PE ratio of -6.98 and a beta of 3.30. Omeros has a one year low of $8.66 and a one year high of $27.09.
ILLEGAL ACTIVITY NOTICE: “HC Wainwright Analysts Give Omeros (OMER) a $30.00 Price Target” was first reported by BBNS and is the property of of BBNS. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://baseballnewssource.com/markets/hc-wainwright-analysts-give-omeros-omer-a-30-00-price-target/1907540.html.
Omeros Company Profile
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.